Enables the scalable production of high-purity siRNA and sgRNAs for CRISPR-based gene editing drugs.
Rationally designed to enhance mRNA translation efficiency by reducing IFIT1-mediated immune suppression.
Plasmid linearization integrated with in vitro transcription (IVT) into a single streamlined step, accelerating timelines and improving mRNA quality and batch-to-batch consistency
Proprietary purification and QC workflows deliver mRNA with >98% full-length integrity and <0.01% dsRNA, setting new benchmarks in quality.
Demand for nucleic acid therapeutics (NATs) is expanding as mRNA and oligonucleotide therapeutics advance beyond rare diseases into high-prevalence indications, particularly cardiometabolic conditions such as hypertension and dyslipidemia. For example,...
Developing RNA therapeutics requires years of scientific innovation and dedicated investment. However, advancing a promising preclinical candidate into clinical development—and ultimately commercial production—presents a major manufacturing challenge: scalability. Manufacturers must...
In recent years, dual-targeting oligonucleotide drugs have become one of the hottest fields in the global pharmaceutical industry due to their advantages of synergistic effects and avoiding combination therapy. Despite...
The growing range of nucleic acid therapeutics (NATs), including oligonucleotide drugs such as siRNA, mRNA therapeutics, and CRISPR-based gene-editing therapies, is reshaping modern medicine. As these modalities advance through clinical...
Hypercholesterolemia is one of the most common chronic metabolic disorders. Its core characteristic is abnormally elevated levels of "bad cholesterol," or low-density lipoprotein cholesterol (LDL-C), which can form atherosclerotic plaques...
Introduction The widespread application of CRISPR-Cas technology in the gene editing field is driving rapid growth in the demand for sgRNA synthesis. However, the traditional SPOS (Solid-Phase Oligonucleotide Synthesis) method...
Introduction siRNA, as a type of RNA interference (RNAi) technology, has demonstrated significant value and potential in the fields of gene silencing and targeted therapy. During the development of siRNA...
Advancements in RNA therapeutics are increasing the demand for high-quality synthetic oligonucleotides including siRNA (small interfering RNA) and sgRNA (single guide RNA). While conventional solid-phase oligonucleotide synthesis (SPOS) remains the...